Hypertension in adults: confirmation, cardiovascular risk and treatment approach

Clinical scope and measurement quality

Hypertension is usually asymptomatic, yet its cumulative association with stroke, coronary disease, heart failure, chronic kidney disease and vascular death makes reliable diagnosis and sustained treatment important. The first clinical task is therefore not to react to an isolated number but to obtain measurements that are technically sound and representative. Cuff size, posture, recent exertion, conversation, pain and anxiety can all affect readings. If the clinic reading is raised, repeat measurements during the consultation and record the lower of the last two where the NICE pathway directs.

An unexpectedly severe blood-pressure elevation should trigger a search for symptoms or signs of acute target-organ damage rather than automatic outpatient classification. New neurological deficit, acute chest pain, pulmonary oedema, encephalopathy, retinal emergency or another concerning presentation requires urgent assessment according to local pathways. In an otherwise stable patient, confirmation outside the clinic is usually the key next step.

Confirming hypertension with ABPM or HBPM

NICE recommends ambulatory blood-pressure monitoring, when suitable, to confirm a clinic blood pressure in the hypertensive range below the level requiring same-day specialist assessment. ABPM reduces the risk of diagnosing white-coat hypertension and provides information across the person’s usual day. A valid protocol uses repeated daytime measurements and an average based on sufficient readings. If ABPM is unsuitable or not tolerated, structured home blood-pressure monitoring is an accepted alternative.

Home monitoring should be taught rather than treated as a casual series of readings. Measurements are usually taken twice, at least a minute apart, morning and evening for several days, with the first day excluded from the diagnostic average in the NICE approach. The result should be interpreted using out-of-office thresholds rather than the clinic threshold. A marked mismatch between clinic and home or ambulatory values may represent white-coat or masked hypertension and influences follow-up.

Baseline assessment and secondary causes

After hypertension is confirmed, evaluate cardiovascular risk and evidence of organ involvement. A typical assessment includes urine albumin-to-creatinine ratio and testing for haematuria, glycated haemoglobin, electrolytes, creatinine and estimated GFR, lipids, retinal examination for hypertensive retinopathy and a 12-lead ECG. Findings may change both urgency and treatment choices. Chronic kidney disease, diabetes, established cardiovascular disease and target-organ damage are especially important when discussing treatment thresholds.

Consider whether the pattern suggests a secondary cause. Younger age at presentation, resistant hypertension, abrupt deterioration, hypokalaemia, episodic symptoms suggesting catecholamine excess, renal disease, obstructive sleep apnoea, endocrine disease or relevant medicines can justify targeted investigation. Medication reconciliation should include prescribed agents, over-the-counter products, stimulants, corticosteroids and substances that may raise blood pressure. Secondary-cause testing should be hypothesis driven rather than indiscriminate.

Lifestyle and cardiovascular risk reduction

Lifestyle measures remain part of management even when medication is required. Discussions should address dietary salt, weight, physical activity, alcohol intake and smoking. Advice is more effective when linked to the person’s priorities and comorbidity rather than presented as a generic list. Potassium-containing salt substitutes are not appropriate for everyone, particularly where hyperkalaemia risk is increased, so broad dietary advice should account for kidney function and medicines.

Hypertension is one component of overall vascular risk. Lipid management, diabetes care, smoking cessation and antiplatelet therapy when separately indicated should be considered through their own evidence-based pathways. Treating blood pressure does not remove the need to assess these other risks. Shared decision making is particularly important when the absolute benefit of pharmacological treatment is modest or where frailty, multimorbidity or treatment burden changes the balance.

Starting and selecting antihypertensive treatment

The decision to start medication depends on the confirmed blood-pressure stage, age, cardiovascular risk, target-organ damage and relevant comorbidity. NICE recommends drug treatment for persistent stage 2 hypertension and supports treatment in stage 1 hypertension when additional risk features are present, with individualised discussion in lower-risk groups and older adults. Severe hypertension with concerning target-organ findings follows a more urgent pathway.

Initial drug class is selected using age, type 2 diabetes and ethnicity as key factors, followed by stepwise combination treatment when control is insufficient. ACE inhibitors or angiotensin-receptor blockers, calcium-channel blockers and thiazide-like diuretics form the main NICE treatment sequence. Drug-specific contraindications, renal function, electrolytes, pregnancy potential, adverse effects and interacting treatment must be considered. The rationale for the chosen class and the planned review interval should be documented so that escalation is based on response rather than prescription inertia.

Targets, monitoring and resistant hypertension

Treatment targets differ by age and by some comorbid conditions. For many adults under 80, NICE uses a clinic target below 140/90 mmHg, with a corresponding lower out-of-office target. For adults aged 80 and over, the clinic target is less stringent, and clinical judgement is emphasised in frailty and multimorbidity. Some people with diabetes or chronic kidney disease have condition-specific target considerations, so the relevant linked guideline should be checked rather than applying a single number to every patient.

When blood pressure remains above target, first confirm adherence, measurement accuracy and the adequacy of current doses. Review substances that can raise blood pressure and consider white-coat effect before labelling resistant hypertension. People uncontrolled on an appropriate three-drug regimen may need a fourth agent or specialist advice, with potassium and kidney function guiding choices. Home monitoring can be useful for ongoing management when the patient is trained and the results are integrated into an agreed plan.

Practice points and limitations

The commonest practical problems are diagnosing from an isolated clinic reading, failing to confirm with ABPM or structured HBPM, escalating treatment without checking adherence and technique, overlooking target-organ damage, and applying a treatment target without considering age or comorbidity. Good documentation should include the diagnostic method, baseline risk assessment, treatment rationale and monitoring plan.

This reference summarises the main NICE approach rather than every threshold, exception or medicine-specific detail. Current NICE visual summaries, the full NG136 recommendations, local formularies and the relevant product information should be used when making prescribing decisions. Hypertension in pregnancy, acute hypertensive emergencies and paediatric hypertension require separate pathways.

Documentation, adherence and longitudinal review

A hypertension record should make the diagnostic pathway easy to reconstruct. Record the clinic readings that triggered investigation, the ABPM or HBPM average used to confirm the diagnosis, relevant target-organ assessment and the cardiovascular-risk context. This matters because a later isolated clinic reading may otherwise be mistaken for the basis of diagnosis. If out-of-office monitoring was not possible, document why and which alternative approach was used.

Apparent treatment resistance frequently reflects factors other than pharmacological failure. At review, ask how medicines are actually taken, whether doses are missed because of adverse effects or practical barriers, and whether the patient understands the purpose of each medicine. Pharmacy refill history, home readings and direct review of technique can provide a more accurate picture than a simple adherence question. Address adverse effects early because a tolerable regimen taken consistently is more useful than a theoretically ideal regimen that the patient does not use.

Longitudinal review should connect blood pressure with renal function, electrolytes, symptoms, falls risk and the broader cardiovascular plan. Treatment may need adjustment after weight change, acute illness, new kidney disease, addition of interacting medicines or development of frailty. Encourage patients who self-monitor to bring readings in a structured format and agree how often measurements are useful; repeated checking without a plan can increase anxiety without improving management. Where readings are consistently controlled, review frequency can reflect overall risk rather than the presence of the diagnosis alone.

Clinical context also matters when readings are close to thresholds. Pain, acute anxiety, sleep deprivation, recent caffeine, intercurrent illness and medication changes can transiently alter blood pressure. Rather than creating a diagnosis from a short-lived circumstance, repeat or out-of-office measurement can clarify the baseline. Conversely, normal clinic readings should not end investigation when there is convincing evidence of masked hypertension or target-organ damage. The aim is a defensible estimate of usual blood pressure that can support proportionate long-term treatment.